Sahil D. Doshi, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Bladder cancer
- Genitourinary cancers and conditions
- Kidney (renal cell) cancer and conditions
My Specialties
- Clinical trials
- Immunotherapy
- Targeted therapy
Get to Know Me
I am a medical oncologist with special training in the care of people with genitourinary cancers, including kidney cancer, bladder cancer, prostate cancer, and testicular cancers. I see patients at the Sidney Kimmel Center for Prostate and Urologic Cancers in Manhattan and at Memorial Sloan Kettering Bergen in New Jersey.
My passion for helping others, combined with my scientific curiosity, drew me to the field of oncology (cancer care). I find the relationship between a patient and their oncologist to be deeply meaningful. This makes me committed to building strong relationships with every person I provide care for.
I recognize that a cancer diagnosis can affect all parts of your life. This is why I focus on clear communication and shared decision-making. I want every patient to understand their options and feel confident in the care we choose together. I also aim to balance effective treatment with quality of life, making sure that your values and goals are always a part of the conversation.
At Memorial Sloan Kettering Cancer Center, I work with a team of expert surgeons, pathologists, radiation oncologists, radiologists, and palliative care specialists to provide well-rounded, personalized care. I also work with our dedicated nurses, social workers, and support staff who help patients and their loved ones through every step of treatment.
My research focuses on improving the quality of life and satisfaction of people living with cancer and developing new treatments for kidney cancer. Through clinical trials, we offer patients access to promising therapies before they become widely available. I am also exploring innovative ways to deliver care that is safe, effective, and accessible to all patients, such as using telemedicine and home-based cancer therapy to reduce time spent on treatment and improve patient satisfaction.
My goal is to guide you through your cancer diagnosis and treatment with compassion, care, and teamwork. With the support of the entire care team at MSK, I will be by your side every step of the way, helping you get the expert care you deserve.
Outside of work, I enjoy playing tennis, traveling, and exploring new neighborhoods and restaurants.
I'm a genitourinary (GU) medical oncologist, which is a cancer doctor who specializes in genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.
- Assistant Attending Physician
Conditions I Treat
- Bladder cancer
- Genitourinary cancers and conditions
- Kidney (renal cell) cancer and conditions
- Prostate cancer and conditions
- Testicular germ cell tumors
My Specialties
- Clinical trials
- Immunotherapy
- Targeted therapy
- Telemedicine
Education
- MD, Perelman School of Medicine at the University of Pennsylvania
- BA, University of Pennsylvania
Residencies
- Internal Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital
Fellowships
- Medical Oncology / Hematology, Memorial Sloan Kettering Cancer Center
Board Certifications
- Medical Oncology
- Internal Medicine
Awards and Honors
- Conquer Cancer Young Investigator Award, American Society of Clinical Oncology (2024)
- Merit Award, American Society of Clinical Oncology (2024, 2025)
- Oncology-focused Postdoctoral Training in Care Delivery and Symptom Science (OPTICS) T32 Training Program, National Cancer Institute (2023-2025)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, EPO, HMO
In Network Coverage Type
State Government
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
State Government
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO/EPO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Doshi
- A Phase 2 Study of Cemiplimab and Fianlimab Before Surgery in People With Kidney Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
- Doshi SD, Malling CD, Landrum KM, et al. Opportunities for Home Cancer Care: The Final Frontier. NEJM Catal Innov Care Deliv. 2025;6(6). Published 2025 May 21.
- Doshi SD, Charvadeh YK, Seier K, et al. Perspectives on Telemedicine Visits Reported by Patients With Cancer. JAMA Netw Open. 2024;7(11):e2445363. Published 2024 Nov 4.
- Doshi SD, Knezevic A, Gonzalez C, et al. Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials. Clin Genitourin Cancer. 2025;23(1):102268.
- Khadem Charvadeh Y, Doshi SD, Seier K, et al. Cancer Patient Perspectives on Clinical Trial Discussion and Informed Consent Through Telemedicine. JCO Oncol Pract. Published online March 18, 2025.
- Doshi SD, Dizman N, Knezevic A, et al. A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma. JCO. 2024;42(16).
Visit PubMed for a full listing of Dr. Doshi’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Sahil D. Doshi discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.